Tempus
1 Article found
Tempus articles
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons.
The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope f
Aug. 1, 2024